Gut microbiota interact with breast cancer therapeutics to modulate efficacy

被引:0
作者
Arnone, Alana A. [1 ]
Ansley, Katherine [2 ,3 ]
Heeke, Arielle L. [3 ,4 ]
Howard-McNatt, Marissa [3 ,5 ]
Cook, Katherine L. [1 ,3 ,5 ]
机构
[1] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27109 USA
[2] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Sect Hematol & Oncol, Winston Salem, NC USA
[3] Atrium Hlth, Wake Forest Baptist Comprehens Canc Ctr, Winston Salem, NC 28203 USA
[4] Atrium Hlth, Levine Canc Inst, Dept Solid Tumor Oncol & Invest Therapeut, Charlotte, NC USA
[5] Wake Forest Univ, Bowman Gray Sch Med, Dept Surg, Winston Salem, NC 27109 USA
关键词
Microbiome; Endocrine-targeting Therapies; Chemotherapy; Immune Checkpoint Blockade; Cyclin-dependent Kinase 4/6 Inhibitors; ESTROGEN; CYCLOPHOSPHAMIDE; CHEMOTHERAPY; DIVERSITY; BACTERIA; THERAPY;
D O I
10.1038/s44321-024-00185-0
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The gut microbiome, or the community of microorganisms residing in the gastrointestinal tract, has emerged as an important factor in breast cancer etiology and treatment. Specifically, the impact of gut bacterial populations on breast cancer therapeutic outcomes is an emerging area of research. The microbiota's role in modifying the pharmacokinetics of chemotherapy and endocrine-targeting therapies can alter drug efficacy and toxicity profiles. In addition, the gut microbiome's capacity to regulate systemic inflammation and immune responses may influence the effectiveness of both conventional and immunotherapeutic strategies for the treatment of breast cancer. Overall, while the bidirectional interactions between the gut microbiome and breast cancer therapies are still being studied, its impact is increasingly recognized. Future research may provide more definitive insights and help develop personalized therapeutic strategies to harness the microbiome to improve breast cancer treatment outcomes.
引用
收藏
页码:219 / 234
页数:16
相关论文
共 50 条
  • [21] Understanding the relationship between breast cancer, immune checkpoint inhibitors, and gut microbiota: a narrative review
    Hrubesz, Gabriella
    Leigh, Jennifer
    Ng, Terry L.
    TRANSLATIONAL BREAST CANCER RESEARCH, 2024, 5
  • [22] Gut microbiota modulate host immune cells in cancer development and growth
    Erdman, Susan E.
    Poutahidis, Theofilos
    FREE RADICAL BIOLOGY AND MEDICINE, 2017, 105 : 28 - 34
  • [23] The immunoregulatory role of gut microbiota in the incidence, progression, and therapy of breast cancer
    Xue, Kaiyang
    Li, Jiawei
    Huang, Ruijie
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2024, 14
  • [24] Current and future research on the association between gut microbiota and breast cancer
    Liu, Kuan
    Jia, Nan
    Shi, Hongyun
    Ran, Yuge
    FRONTIERS IN MICROBIOLOGY, 2023, 14
  • [25] Crosstalk between gut microbiota and cancer chemotherapy: current status and trends
    Yang, Shanshan
    Hao, Shaodong
    Ye, Hui
    Zhang, Xuezhi
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [26] Gut Microbiota Shapes the Efficiency of Cancer Therapy
    Ma, Weidong
    Mao, Qixing
    Xia, Wenjie
    Dong, Gaochao
    Yu, Changhua
    Jiang, Feng
    FRONTIERS IN MICROBIOLOGY, 2019, 10
  • [27] The role of gut microbiota and metabolites in cancer chemotherapy
    Li, Shiyu
    Zhu, Shuangli
    Yu, Jun
    JOURNAL OF ADVANCED RESEARCH, 2024, 64 : 223 - 235
  • [28] The Gut Microbiota in Causation, Detection, and Treatment of Cancer
    Murphy, Clodagh L.
    O'Toole, Paul W.
    Shanahan, Fergus
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 (07) : 1036 - 1042
  • [29] Colorectal cancer and gut microbiota studies in China
    Wang, Zikai
    Dan, Wanyue
    Zhang, Nana
    Fang, Jingyuan
    Yang, Yunsheng
    GUT MICROBES, 2023, 15 (01)
  • [30] Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota
    Pflug, Natali
    Kluth, Sandra
    Vehreschild, Joerg J.
    Bahlo, Jasmin
    Tacke, Daniela
    Biehl, Lena
    Eichhorst, Barbara
    Fischer, Kirsten
    Cramer, Paula
    Fink, Anna-Maria
    von Bergwelt-Baildon, Michael
    Stilgenbauer, Stephan
    Hallek, Michael
    Cornely, Oliver A.
    Vehreschild, Maria J. G. T.
    ONCOIMMUNOLOGY, 2016, 5 (06):